Vical Receives US Patent For Universal Influenza Vaccine Approach
To provide protection against circulating seasonal strains and emerging pandemic strains of influenza viruses
Vical has received US Patent No. 7537768, covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses.
Vical's DNA vaccine technology can induce both antibody and T-cell immune responses against the target portions of the virus, potentially providing a level of protection not available with conventional influenza vaccines.
In addition, a vaccine based on this approach may have the potential to provide protection against future pandemic threats from new strains of influenza viruses.
The follow-on NP and M2 DNA components could be used in a universal influenza vaccine with the potential to protect against a broad range of circulating or emerging influenza strains.
Related Insight
Suppliers Directory
NDA - Regulatory Affairs and Development Consultancy Partner
NDA is the pharmaceutical industry's leading European regulatory affairs and development consultancy partner, as confirmed by the unsurpassed success history in recent European regulatory accomplishments. In 2009 NDA advised on 33% of all products approved centrally in the EU.
Suppliers
Trigona – Synthesis Development and Kilogram Synthesis
Trigona oHG, a privately-held chemical company, is engaged in the synthesis, development and multi-kilogram manufacturing of chemical products.
Suppliers
BioCis Pharma - ProtoDynamic Therapy Technology
BioCis Pharma is a clinical stage drug development company with the business idea to design and develop novel pharmaceutical products based on its proprietary technology platform.
Suppliers
IRIS Biotech - Peptide Synthesis and Pharmaceutical Intermediates
IRIS Biotech is specialised in reagents for peptide synthesis, PEGylation, life science research and biocatalysis.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
HPLC Analysis of lysozyme in different types of wine
Published by Tosoh Bioscience
White Papers
Ideas About the Future of the Innovative Pharmaceutical Industry
Published by Kinapse
White Papers
Go Digital or Die
Published by NNIT
White Papers
Quality By Design: The Automated Pharmaceutical Assay
Published by Sotax
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.